S
DNTH icon

SignatureFD’s Dianthus Therapeutics DNTH Stock Holding History

SignatureFD’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.8K Sell
80
-44
-35% -$3.84K ﹤0.01% 2732
2026
Q1 		$10.4K Buy
124
+109
+727% +$6.31K ﹤0.01% 2493
2025
Q4 		$618 Buy
15
+7
+88% +$271 ﹤0.01% 3195
2025
Q3 		$315 Hold
8
– – ﹤0.01% 3243
2025
Q2 		$149 Buy
+8
New +$150 ﹤0.01% 3188
2021
Q4 		– Sell
-5
Closed -$1K – 3139
2021
Q3 		$1K Buy
+5
New +$583 ﹤0.01% 2807

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

SignatureFD's DNTH Position: Q2 2026 in Review

SignatureFD reduced its Dianthus Therapeutics (DNTH) stake by 35% in Q2 2026, selling an estimated $3.84K and leaving 80 shares worth $7.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

SignatureFD first reported a position in DNTH in Q3 2021 and has held it in 6 quarters since. The position peaked at $10.4K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • SignatureFD held 80 shares of Dianthus Therapeutics worth $7.8K as of Q2 2026.
  • SignatureFD sold 44 Dianthus Therapeutics shares in Q2 2026, an estimated $3.84K.
  • Dianthus Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2732 holding.
  • SignatureFD first reported a position in Dianthus Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • SignatureFD's Dianthus Therapeutics position peaked at $10.4K in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.